Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Pulmatrix, Inc. (PULM) Starts Presentation at Marcum MicroCap Conference

Posted on June 2, 2016 by MissionIR

Pulmatrix NASDAQ: PULM) is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease  using its clinically validated, proprietary iSPERSE technology. The company’s PUR0200 is a branded generic in clinical development for chronic obstructive pulmonary disease. Pulmatrix’s proprietary product pipeline is focused on advancing treatments for rare diseases, including an inhaled anti-fungal for patients with cystic fibrosis. For more information, visit the company’s website at www.pulmatrix.com

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.